Algert Global LLC Takes Position in Cerus Co. (NASDAQ:CERS)

Algert Global LLC purchased a new stake in Cerus Co. (NASDAQ:CERS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 55,086 shares of the biotechnology company’s stock, valued at approximately $97,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Hood River Capital Management LLC bought a new stake in shares of Cerus during the first quarter worth about $566,000. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of Cerus by 2.4% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,750,700 shares of the biotechnology company’s stock valued at $14,649,000 after purchasing an additional 182,629 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Cerus by 4.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 192,873 shares of the biotechnology company’s stock valued at $365,000 after buying an additional 8,982 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in Cerus by 451.1% during the first quarter. Russell Investments Group Ltd. now owns 14,879 shares of the biotechnology company’s stock worth $28,000 after buying an additional 12,179 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its position in Cerus by 124.8% in the 1st quarter. BNP Paribas Financial Markets now owns 218,647 shares of the biotechnology company’s stock valued at $413,000 after buying an additional 121,364 shares during the last quarter. Institutional investors own 78.37% of the company’s stock.

Insider Buying and Selling

In other news, CFO Kevin Dennis Green sold 28,385 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $2.18, for a total transaction of $61,879.30. Following the completion of the sale, the chief financial officer now directly owns 590,365 shares of the company’s stock, valued at $1,286,995.70. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, insider Richard J. Benjamin sold 21,605 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $2.50, for a total value of $54,012.50. Following the transaction, the insider now owns 438,007 shares in the company, valued at approximately $1,095,017.50. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Kevin Dennis Green sold 28,385 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $2.18, for a total value of $61,879.30. Following the completion of the sale, the chief financial officer now owns 590,365 shares in the company, valued at approximately $1,286,995.70. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.40% of the stock is currently owned by corporate insiders.

Cerus Price Performance

CERS opened at $1.82 on Friday. The firm’s fifty day moving average price is $2.02 and its two-hundred day moving average price is $1.93. The company has a market capitalization of $336.50 million, a price-to-earnings ratio of -10.71 and a beta of 1.18. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.51 and a quick ratio of 1.83. Cerus Co. has a 1 year low of $1.21 and a 1 year high of $2.59.

Cerus (NASDAQ:CERS) last posted its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.01. Cerus had a negative net margin of 14.15% and a negative return on equity of 44.27%. The firm had revenue of $45.08 million during the quarter, compared to analyst estimates of $42.50 million. During the same quarter last year, the business posted ($0.07) EPS. As a group, analysts anticipate that Cerus Co. will post -0.13 earnings per share for the current fiscal year.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.